Free Trial
LON:VAL

ValiRx (VAL) Share Price, News & Analysis

GBX 2.80
+0.15 (+5.66%)
(As of 07/12/2024 ET)
Today's Range
2.72
3
50-Day Range
1.90
4
52-Week Range
1.85
15
Volume
1.22 million shs
Average Volume
1.24 million shs
Market Capitalization
£3.71 million
P/E Ratio
N/A
Dividend Yield
0.63%
Price Target
N/A
VAL stock logo

About ValiRx Stock (LON:VAL)

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Nuneaton, the United Kingdom.

VAL Stock Price History

VAL Stock News Headlines

ValiRx (LON:VAL) Trading 10.9% Higher
ValiRx PLC VAL
There’s something very “off” about this situation
The stock is now trading for just $10 a share. Why is this company being ignored by Wall Street, and what kind of gains could shareholders soon be looking at?
There’s something very “off” about this situation
The stock is now trading for just $10 a share. Why is this company being ignored by Wall Street, and what kind of gains could shareholders soon be looking at?
European Stocks Close Mostly Higher
European Markets Move Mostly Higher
ValiRx PLC EAJF
See More Headlines
Receive VAL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ValiRx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
9/07/2020
Today
7/14/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
8
Year Founded
N/A

Profitability

Net Income
£-2,040,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
GBX 0.04 per share
Book Value
GBX 3 per share

Miscellaneous

Free Float
N/A
Market Cap
£3.71 million
Optionable
Not Optionable
Beta
0.63
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Suzanne J. Dilly B.Sc. (Age 46)
    BSc, Ph.D., CEO & Director
    Comp: $154.6k
  • Mr. James Gerry Desler FCA (Age 79)
    CFO, Company Secretary & Executive Director
    Comp: $66.45k
  • Mr. Kumar Nawani
    Head of Operations
  • Dr. Catherine Jane Tralau-Stewart Ph.D.
    Chief Scientific Officer & Board Observer
  • Mr. Mark Treharne
    Corporate Development Manager
  • Dr. Andrew Carnegie
    Head of Strategic Commercial Development

VAL Stock Analysis - Frequently Asked Questions

How have VAL shares performed this year?

ValiRx's stock was trading at GBX 5.90 at the beginning of 2024. Since then, VAL shares have decreased by 52.5% and is now trading at GBX 2.80.
View the best growth stocks for 2024 here
.

How were ValiRx's earnings last quarter?

ValiRx plc (LON:VAL) issued its quarterly earnings results on Monday, September, 7th. The company reported ($4.43) EPS for the quarter.

How do I buy shares of ValiRx?

Shares of VAL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of ValiRx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ValiRx investors own include Petrofac (PFC), boohoo group (BOO), ReNeuron Group (RENE), Falanx Group (FLX), Scirocco Energy Plc (SOLO.L) (SOLO), CyanConnode (CYAN) and IQE (IQE).

This page (LON:VAL) was last updated on 7/14/2024 by MarketBeat.com Staff

From Our Partners